Although other oncogenic and tumor-suppressive genes were predicted in silico, FOXP3 and EGFR were prioritized for their dual mechanistic relevance and translational potential as therapeutic markers in ovarian cancer. This evidence concerns the gene FOXP3 and ovarian carcinoma.